<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222014</url>
  </required_header>
  <id_info>
    <org_study_id>0402308</org_study_id>
    <secondary_id>PHRC</secondary_id>
    <nct_id>NCT00222014</nct_id>
  </id_info>
  <brief_title>TIPS With Coated Stents for Refractory Ascites in Patients With Cirrhosis</brief_title>
  <official_title>TIPS (With Coated Stents) OR PARACENTESIS + ALBUMIN ADMINISTRATION FOR THE TREATMENT OF REFRACTORY ASCITES IN PATIENTS WITH CIRRHOSIS : A RANDOMIZED TRIAL COMPARING SURVIVAL, QUALITY OF LIFE AND NUTRITIONAL STATUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GORE Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main end point of the study is to assess survival in cirrhotic patients with refractory&#xD;
      ascites treated by TIPS (using PTFE covered stents) vs patients treated by paracentesis +&#xD;
      albumin infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnostic evaluation before randomisation includes assessment of clinical hepatic&#xD;
      encephalopathy, usual blood tests, and Doppler-ultrasonography of the abdomen. Inclusion and&#xD;
      exclusion criteria will be checked during the inclusion visit. Informations concerning the&#xD;
      trial will also be given. After the investigator receives written informed consent,&#xD;
      randomisation will be performed online. Randomisation will be centralized, equilibrated for&#xD;
      each center, stratified according to whether cirrhosis is alcoholic or not and adjusted every&#xD;
      ten patients.&#xD;
&#xD;
      I Treatments&#xD;
&#xD;
        1. TIPS :&#xD;
&#xD;
           TIPS will be performed under sedation or general anesthesia with tracheal intubation&#xD;
           according to the usual policy of participating centers. Pre-tips portosystemic pressure&#xD;
           gradient and diameter of the shunt must be notified.&#xD;
&#xD;
           However, for homogeneity reasons the following will be adhered:&#xD;
&#xD;
           A 10 mm Viator stent will be used, that will be dilated to 8 or 10 mm according to the&#xD;
           hemodynamic response. The aim will be to reduce portal pressure gradient (PPG) below 12&#xD;
           mmHg. Ideal PPG should be 7-8 mmHg.&#xD;
&#xD;
        2. Paracentesis + albumin infusion :&#xD;
&#xD;
      After a paracentesis &gt; 3 liters, 8 g of Albumin per liter of extracted ascites must be&#xD;
      infused.&#xD;
&#xD;
      If possible, analysis of ascitic fluid will be performed after each paracentesis for&#xD;
      biochemical, cytological and bacterial analyses.&#xD;
&#xD;
      II Follow up&#xD;
&#xD;
        1. In all patients:&#xD;
&#xD;
           Low salt diet (2 - 4 g/j). Follow up of the patient is as usual. Patients will have a&#xD;
           clinical examination at 1 month and then every 3 months up to 1 year. At each visit,&#xD;
           clinical and biochemical variables needed to calculate Child-Pugh score will be&#xD;
           recorded.&#xD;
&#xD;
           Doppler ultrasonography will be performed at the beginning, 6 and 12 months. Patients&#xD;
           will be followed 1 year or until liver transplantation or death.&#xD;
&#xD;
             1. Nutritional status evaluation:&#xD;
&#xD;
                  -  Weight: M0, M3, M6, M9, M12&#xD;
&#xD;
                  -  Anthropometrics measurements: M0, M3, M6, M12: they will include : triceps&#xD;
                     skinfold thickness, biceps skinfold thickness, brachial circumference.&#xD;
&#xD;
                  -  Biochemical parameters: M0, M3, M6, M12: they will include : albumin,&#xD;
                     pre-albumin, orosomucoïde, C-reactive protein, haptoglobin, natriuresis, 24&#xD;
                     hour urinary excretion of creatinine. Four blood samples will be collected and&#xD;
                     conserved for a posteriori analysis if required (transferrin, retinol binding&#xD;
                     protein, leptin, hormonal dosages). These analyses will be centralized in&#xD;
                     Toulouse (Toulouse center will be charged for the shipment of those blood&#xD;
                     samples).&#xD;
&#xD;
                  -  Physical parameters: dual energy x-ray absorptiometry M0, M12&#xD;
&#xD;
                  -  Grip test M0, M6, M12 [16, 17].&#xD;
&#xD;
             2. Quality of Life :&#xD;
&#xD;
           SF-36 (Short Form 36 (SF-36) Health Survey Questionnaire) at inclusion and then every&#xD;
           three months [18, 19].&#xD;
&#xD;
        2. Paracentesis + albumin infusion group:&#xD;
&#xD;
           Patients included in this group will be treated by paracentesis whenever required. Eight&#xD;
           grams of albumin per liter of ascites extracted will be infused when more than 3 liters&#xD;
           of ascitic fluid will be removed.&#xD;
&#xD;
        3. TIPS group :&#xD;
&#xD;
      When shunt dysfunction will be suspected because of relapse of ascites or incomplete response&#xD;
      2 months after the procedure, an angiography and PPG measurement will be performed. If shunt&#xD;
      dysfunction is confirmed, angioplasty or PTFE re-stenting will aim at reducing PPG below 12&#xD;
      mmHg.&#xD;
&#xD;
      III Definition of treatment failure:&#xD;
&#xD;
      After TIPS: relapse of ascites requiring at least 2 paracenteses or persistence after 2&#xD;
      months will be considered as treatment failure. A hemodynamic and angiographic control will&#xD;
      be performed. Patients will be treated by refection of the shunt. If severe encephalopathy&#xD;
      occurs and persists despite treatment, the diameter of the shunt should be decreased or the&#xD;
      TIPS occluded. Total occlusion of the shunt or relapse of ascites after the reduction of its&#xD;
      diameter will be also considered treatment failures.&#xD;
&#xD;
      In the group treated by paracentesis + albumin infusion, patients having more than 6&#xD;
      paracenteses within 3 months will be considered for alternative treatment (TIPS,&#xD;
      transplantation). Technical impossibility or refusal of the patient to proceed with&#xD;
      paracenteses will be also considered treatment failure. In these cases, a TIPS could also be&#xD;
      proposed.&#xD;
&#xD;
      All these patients with treatment failure must be followed up to one year after inclusion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at one year</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life, nutritional status, occurrence of complications (other than ascites) secondary to portal hypertension.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TIPS réalisé avec prothèse couverte de PTFE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paracenthese and albumine perfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TIPS</intervention_name>
    <description>Transjugular intrahepatic portosystemic shunt with covered PTFE</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paracenthese</intervention_name>
    <description>Paracenthese</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients of both sexes, with cirrhosis, as documented by previous liver-biopsy or&#xD;
             usual clinical and biochemical stigmata&#xD;
&#xD;
          -  with refractory or recurrent ascites as defined in chapter IV&#xD;
&#xD;
          -  who signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients not fulfilling inclusion criteria&#xD;
&#xD;
          -  patients having needed more than 6 paracenteses within the last 3 months&#xD;
&#xD;
          -  patients expected to be transplanted within the next 6 months&#xD;
&#xD;
          -  usual contra-indication for TIPS : congestive heart failure NYHA&gt;III or medical&#xD;
             history of pulmonary hypertension, portal vein thrombosis, hepatic polycystosis,&#xD;
             intra-hepatic bile ducts dilatation, spontaneous clinical recurrent hepatic&#xD;
             encephalopathy&#xD;
&#xD;
          -  hepatocarcinoma on the expected tract of the shunt&#xD;
&#xD;
          -  severe liver failure as defined by : Prothrombin index &lt; 35 % or total bilirubin &gt; 100&#xD;
             micromol/l or Child Pugh Score &gt;12&#xD;
&#xD;
          -  serum creatinine &gt; 250 micromol/l&#xD;
&#xD;
          -  uncontrolled sepsis&#xD;
&#xD;
          -  known allergy to albumin&#xD;
&#xD;
          -  pregnant or breast feeding women&#xD;
&#xD;
          -  refusal to participate or patient unable to receive informations or to sign written&#xD;
             informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BUREAU Christophe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépato-Gastro-Entérologie, Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, Perreault P, Péron JM, Abraldes JG, Bouchard L, Bilbao JI, Bosch J, Rousseau H, Vinel JP. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004 Feb;126(2):469-75.</citation>
    <PMID>14762784</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory ascites</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Paracentesesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

